You are here: Industry Insights > Bamlanivimab

News List

Lilly's Bamlanivimab and Etesevimab Gain EUA for Pediatric Use contractpharma
December 07, 2021
Expanded authorization based on safety and efficacy in phase 2/3 BLAZE-1 trial in mild to moderate COVID-19 and high risk patients.
Lilly India gets nod for restricted EU of monoclonal antibody drugs, bamlanivimab and etesevimab to treat COVID-19 expresspharma
June 02, 2021
Bamlanivimab and etesevimab together have been authorised under Emergency Use Authorization in the US and select EU countries, for the treatment of mild to moderate COVID-19.
COVID-19 monoclonal antibodies reduce risk of hospitalization and death worldpharmanews
May 20, 2021
Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer complications of the disease, according to an analysis of UPMC patients who received ...
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries worldpharmanews
May 11, 2021
Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic.
Monoclonal antibodies against COVID-19 have high potential, but efficacy against emerging variants muddled: GlobalData expresspharma
April 23, 2021
The prevalence of more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy.
FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab worldpharmanews
April 19, 2021
The U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in ...
Lilly Modifies Purchase Agreement with U.S. for COVID Therapies contractpharma
April 13, 2021
Bamlanivimab and etesevimab agreement modified to enable the supply of etesevimab to complement doses of bamlanivimab the U.S. government already purchased.
AbCellera reports bamlanivimab’s potency against SARS-CoV-2 in study pharmaceutical-technology
April 06, 2021
AbCellera (ABCL) has reported that bamlanivimab (LY-CoV555) demonstrated high potency in neutralising SARS-CoV-2 by uniquely binding both up and down confirmations of the spike receptor-binding domain (RBD) in preclinical study.
Lilly, Vir and GSK report positive data from Covid-19 antibody trial pharmaceutical-technology
March 30, 2021
Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline (GSK) have reported topline data from the expanded Phase II BLAZE-4 trial of bamlanivimab (LY-CoV555) co-administered with VIR-7831 (GSK4182136) in low-risk adult patients with mild to ...
Eli Lilly Stops Distribution of Bamlanivimab as COVID-19 Treatment americanpharmaceuticalreview
March 29, 2021
The US government in coordination with Eli Lilly said it will no longer distribute the COVID-19 monoclonal antibody therapy bamlanivimab for use on its own.

Previous page 1 2 3 4 Next page